China Extract Powder For Use As Dietary Supplement Extract Powder, Extract Powder Manufacturer Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.kangnewpharma.com
Christian Beyer, MD, a researcher at the University of Erlangen-Nuremberg in Germany, said: "Our research is the first study to determine these biomarkers based on a large population cohort." He explained: "(Research) results show that we will be the first The ability to predict the risk of severe osteoarthritis before the disease begins to threaten the lives of patients. This will enable us to take precautions as early as possible to reduce the impact of the disease on patients' lives and the social and economic burden."
Currently, in many fields, miRNAs are being used as biomarkers, including cancer, diabetes, and cardiovascular disease. Dr. Beyer believes: "They can be stable at different temperatures and conditions and can be determined in the blood." He presented the results at the 2014 European Union of Anti-Rheum Union (EULAR) conference.
The researchers evaluated serum samples from patients with osteoarthritis in the Bruneck cohort from 1995 to 2010. The primary outcome measure was the need for hip or knee replacement surgery. During the follow-up period, 67 of 816 patients underwent at least 1 joint replacement due to severe knee or hip osteoarthritis. The age of these patients was significantly older than those without surgery (p=0.053) and the body mass index was higher (p=0.002).
Existing blood samples are used for expression testing of baseline miRNAs. The researchers identified 12 of the approximately 374 miRNAs as candidate biomarkers. In the Cox regression analysis, they found that three of these miRNAs were associated with replacements requiring hip or knee joints: miR-454, miR-885-5p, and let-7e.
Dr. Beyer reports: "The most promising single miRNA is let-7e, the lower the let-7e level, the higher the need for surgery for osteoarthritis of the knee or hip. The study also proposes many The new question, where do these miRNAs rise? In diseased joints, do they affect the activity of the disease? Should we verify these (miRNAs) in other cohorts?"
He noted that the study cohort consisted of heterogeneous populations in a small hospital and noted that these findings needed to be confirmed in a larger study. Several studies are currently underway to determine if these biomarkers can be used in clinical practice.
Use <br> <br> an expert in clinical practice that this may soon happen. These biomarkers should enter clinical practice sooner rather than later, said Ulf Müller-Ladner, MD, president of the European Anti-Rheum Union (EULAR) Science Program at the University of Giessen, Germany, and director of the Department of Rheumatology.
Dr. Müller-Ladner said: “Small miRNAs are easy to detect. If you choose the right test, you can predict or diagnose the disease.†Once these findings are confirmed in a larger study, they can be used clinically. He said: "Now miRNAs are also being used in other diseases. They are easy to detect and are not affected by temperature." He explained that if a patient has a mother who is in a wheelchair because of osteoarthritis, "then You will be able to discuss the expected course of the disease. If the patient has a serious disease biomarker, then you can encourage them to lose weight and exercise and treat them more enthusiastically."
The first biomarkers for severe osteoarthritis
Introduction: New research suggests that the presence of three specific tiny (mi) RNAs in the blood seems to predict the ultimate progression of severe osteoarthritis.